Stay updated on Ipragliflozin vs Sitagliptin in T2DM with SU+Met Clinical Trial

Sign up to get notified when there's something new on the Ipragliflozin vs Sitagliptin in T2DM with SU+Met Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Ipragliflozin vs Sitagliptin in T2DM with SU+Met Clinical Trial page

  1. Check
    3 days ago
    Change Detected
    Summary
    The site footer revision changed from v3.7.0 to v3.7.1 while the page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-13T05:55:56.000Z thumbnail image
  2. Check
    10 days ago
    No Change Detected
  3. Check
    17 days ago
    No Change Detected
  4. Check
    24 days ago
    Change Detected
    Summary
    Access to the study record is blocked, as the page now renders a 403 Forbidden error instead of the study details. The interface shows the 403 message and site footer, with the previous content no longer visible.
    Difference
    19%
    Check dated 2026-09-21T23:57:26.000Z thumbnail image
  5. Check
    45 days ago
    Change Detected
    Summary
    The revision label on the page has been updated from v3.6.5 to v3.6.6, indicating a newer version of the page content. This is a metadata update and does not affect the study details or participant information.
    Difference
    0.1%
    Check dated 2026-08-31T18:45:42.000Z thumbnail image
  6. Check
    66 days ago
    Change Detected
    Summary
    Revision updated from v3.6.4 to v3.6.5, signaling a minor backend/template update to the page.
    Difference
    0.1%
    Check dated 2026-08-10T16:22:40.000Z thumbnail image
  7. Check
    81 days ago
    Change Detected
    Summary
    Type 2 diabetes was added as a topic and 'related topics: MedlinePlus Genetics' were added in the page's contextual links. The site revision label was updated from v3.6.3 to v3.6.4 in the footer.
    Difference
    0.2%
    Check dated 2026-07-27T06:35:05.000Z thumbnail image
  8. Check
    88 days ago
    Change Detected
    Summary
    Type 2 diabetes and related topic references, including MedlinePlus Genetics, have been removed from the page, reducing the explicit disease context shown to readers. The change affects how the study's condition is described and what related resources are visible to users.
    Difference
    0.2%
    Check dated 2026-07-20T02:20:41.000Z thumbnail image

Stay in the know with updates to Ipragliflozin vs Sitagliptin in T2DM with SU+Met Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Ipragliflozin vs Sitagliptin in T2DM with SU+Met Clinical Trial page.